Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fitusiran · Qfitlia, SAR439774

Oligonucleotide (siRNA) · Gene silencing: antithrombin (SERPINC1) · developed by Genzyme

Approved FDA, Mar 2025
SNY Developer

What is Fitusiran?

Fitusiran is a double-stranded small interfering RNA that binds antithrombin (AT) messenger RNA and degrades it through RNA interference, reducing plasma AT levels. It is studied in hemophilia, a bleeding disorder, and is given subcutaneously.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Qfitlia, SAR439774
Drug type
Oligonucleotide (siRNA)
Targets
antithrombin (SERPINC1)
Mechanism
Gene silencing: antithrombin (SERPINC1)
Pathways
RNA interference, coagulation cascade
Therapy area
Hematology
Developer
Genzyme Corp (SNY)
FDA status
Approved as Qfitlia (March 28, 2025), NDA219019 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 16, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Hemophilia

More from Genzyme

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Fitusiran

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.